You are here: Industry Insights > LDL-C

News List

FDA Approves Leqvio (inclisiran), First-in-Class siRNA to Reduce Low-Density Lipoprotein Cholesterol (LDL-C) Drugs
December 27, 2021
Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio® (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol...
Novo Nordisk BASEA office certified Best Place to Work for 2021 prnasia
December 24, 2021
Today, Akeso, Inc. (09926.HK) announces that Ebronucimab (PCSK9 monoclonal antibody, research and development code: AK102), jointly developed by the Company and Dawnrays Biotechnology Capital (Asia) Ltd.
FDA approves add-on therapy for patients with genetic form of severely high cholesterol americanpharmaceuticalreview
April 07, 2021
FDA has approved Praluent (alirocumab) injection for adult patients with homozygous familial hypercholesterolemia (HoFH), a genetic condition that causes severely high cholesterol. Praluent is not intended to be used alone but instead added to other ...
FDA Approves Evkeeza americanpharmaceuticalreview
February 22, 2021
Regeneron Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approved EvkeezaTM (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat adult and pediatric patients aged 12 ...
NewAmsterdam Pharma raises $196m through Series A funding round pharmaceutical-technology
January 18, 2021
Clinical stage company NewAmsterdam Pharma (NAP) has raised $196m (€160m) through Series A funding round to support the full Phase III development of its ApoB and LDL-c lowering small molecule drug, obicetrapib.
Lupin gets US FDA approval for Colesevelam Hydrochloride Tablets expresspharma
December 21, 2020
They are indicated for reducing elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.
AstraZeneca Initiates Study of Antisense Med Targeting PCSK9 to Lower LDL-Cholesterol americanpharmaceuticalreview
December 17, 2020
Ionis Pharmaceuticals announced that biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical trial of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels in patients with dyslipidemia by ...
Novartis analysis shows inclisiran lowers LDL-C with high consistency expresspharma
August 31, 2020
The analysis evaluated the efficacy and tolerability of inclisiran on top of a maximally tolerated dose of statins, in two studies of more than 2,300 patients (of which 1,164 were on inclisiran).
Esperion Announces Commercial Availability of NEXLIZET americanpharmaceuticalreview
June 15, 2020
Esperion announced NEXLIZETTM (bempedoic acid and ezetimibe) tablets, the first approved oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering combination medicine is now available in the U.S.
FDA approves Esperion’s non-statin LDL-C lowering drug pharmaceutical-technology
March 03, 2020
Esperion has announced the US Food and Drug Administration (FDA) has approved Nexlizet (bempedoic acid and ezetimibe).

Previous page 1 2 Next page